Grand River Aseptic Manufacturing (GRAM), a parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense. Under the agreement, GRAM will invest $160 million and receive $120 million from the U.S. government to fund the expansions of its filling and finishing facilities.

GRAM’s state of the art facilities and equipment enable the company to deliver life-saving cGMP manufacturing capabilities for pharmaceutical companies and the U.S. government. GRAM will continue to utilize its cutting-edge and innovative 80,000 square-foot, large-scale filling facility and 200,000 square-foot finishing center located in Grand Rapids, MI. The pact supports the build-out of floor two in GRAM’s aseptic filling facility, along with a 30,000 square-foot expansion of GRAM’s finishing center, including a sterility laboratory and added warehouse space. The agreement will increase GRAM’s filling capacity to a total of four isolator fill lines and further expands finishing operations with the advanced equipment and technology GRAM is well known.

This agreement stems from GRAM’s accomplishments throughout Operation Warp Speed where GRAM provided fill and finish services in the manufacturing of a COVID-19 vaccine.

“We are honored to support the U.S. government in bringing necessary biopharmaceutical products to market swiftly,” said Tom Ross, president and CEO, Grand River Aseptic Manufacturing. “This new agreement is a testament to the invaluable expertise our organization has gained and assures capacity to handle public health emergencies as they arise with the highest level of efficiency and accuracy.”

Visit GRAM at CPhI NA booth 1005